Methods of making and using a magnetic ECM are disclosed. The ECM comprises positively and negatively charged nanoparticles, wherein one of said nanoparticles contains a magnetically responsive element. When the magnetic ECM is seeded with cells, the cells will be magnetized and can be levitated for 3-D cell culture.

Tumors in portions of a subject's body that have a longitudinal axis (e.g., the torso, head, and arm) can be treated with TTFields by affixing first and second sets of electrodes at respective positions that are longitudinally prior to and subsequent to a target region. An AC voltage with a frequency of 100-500 kHz is applied between these sets of electrodes. This imposes an AC electric field with field lines that run through the target region longitudinally. The field strength is at least 1 V/cm in at least a portion of the target region. In some embodiments, this approach is combined with the application of AC electric fields through the target region in a lateral direction (e.g., front to back and/or side to side) in order to apply AC electric fields with different orientations to the target region.

Methods of synthesizing gold nanodendrites (AuNDs) using amines, such as long chain amines, as a structural directing agent are disclosed. Degree of branching (DB) of the AuNDs can be tuned by adjusting certain synthetic parameters, such as solvent type, and the type and concentration of the long chain amines. DB control results in dramatic tunability of the optical properties of the AuNDs in the near infrared (NIR) range enabling improved performance, for example as a photothermal cancer therapeutic.

A device for providing hyperthermia treatment includes an ultrasound energy generator configured to apply low intensity ultrasound to target tissue. The low intensity ultrasound energy induces therapeutic heating in the tissue at or below the surface of the skin. In order to control the temperature of the tissue during therapy, a microwave radiometer, such as a Dicke radiometer, can be used to measure the temperature of the tissue and feed back the temperature measurement to the ultrasound energy generator to control ultrasonic energy produced and control the temperature of the target tissue.

The present invention relates to a biocompatible photothermal composition that can be used in various fields including the treatment of cancer and skin diseases.

The invention concerns a biocompatible oily ferrofluid comprising iron-oxide based magnetic nanoparticles and an oil phase comprising at least one fatty acid ester, characterized in that said magnetic nanoparticles are surface functionalized by molecules of one or more phospholipids, and in particular a biocompatible oily ferrofluid comprising iron-oxide based magnetic nanoparticles and an oil phase comprising at least one fatty acid ester, said iron-oxide based magnetic nanoparticles forming a colloidal dispersion in said oil phase from a temperature belonging to the range from 20 to 80° C., characterized in that said magnetic nanoparticles are surface functionalized by molecules of one or more phospholipids which do not completely cover the surface of the iron-oxide based magnetic nanoparticles, which in particular ensure a coverage rate of the surface of the iron-oxide based magnetic nanoparticles such that the fatty acid ester(s) present in the oil phase have access to the surface of the iron-oxide based magnetic nanoparticles. The invention also concerns the process for preparing such a biocompatible oily ferrofluid and its use as a contrast agent for magnetic resonance imaging or in the context of a cancer treatment by hyperthermia. Finally, the invention concerns a nanoemulsion comprising such a biocompatible oily ferrofluid.

Provided is a therapeutic agent targeting and fixation medical device that precisely targets a therapeutic agent including a magnetic substance by using an optimized array of magnets in consideration of an affected area of a patient.

The present invention relates to tumor-targeted probes for use as medicaments and for use in treatment of cancer and to methods of treatment wherein such probes are used. The probes consist of a light-absorbing molecule linked directly or via a spacer to a peptide targeting the urokinase-type plasminogen activator receptor (uPAR). When irradiating the light-absorbing molecule of the probe with laser beams from an external source heat will be released locally to tumor cells expressing uPAR resulting in tumor ablation.

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

The present invention relates to treatment of a psychiatric condition, for example resistant depression (RD), bipolar disorder (either threshold or sub-threshold) and/or major depressive disorder via application of repetitive transcranial magnetic stimulation with a drug treatment, in particular application of repetitive transcranial magnetic stimulation with treatment to modulate the activity of the neurones and induce neuroplasticity and the use of Thyroid hormone treatment to increase quantity or activity of thyroid hormones, for example for treatment of thyroid dysfunction. Patients may be selected for treatment by testing for the presence of normal thyroid function.